The mechanism of histone modifications in regulating enzalutamide sensitivity in advanced prostate cancer
Zhite Zhao1, Yuming Jing1, Zhicheng Xu1
1Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.
Abstract:
Prostate cancer (PCa) is the second most common malignant tumor in men worldwide, particularly castration-resistant prostate cancer (CRPC), for which enzalutamide (Enz) resistance is of particular concern. Modifications to histone methylation and acetylation patterns are closely associated with resistance to Enz in these patients. As PCa progresses, cancer cells alter their histone modification patterns, leading to a reduction in Enz treatment efficacy. Signaling pathways in the tumor microenvironment regulate gene expression by affecting the activity of histone-modifying enzymes, further affecting the efficacy of Enz. This review summarizes recent research about changes in histone modification patterns that occur in drug resistance-related genes at different stages of PCa and explores the potential use of combination therapies for reversing this process, providing insights into novel treatment strategies to improve the clinical efficacy of Enz.
Insights
Histone modifications in prostate cancer (PCa) drive resistance to enzalutamide (Enz) treatment. Understanding these changes offers new combination therapy strategies to improve CRPC outcomes.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Prostate cancer (PCa) is a leading global cancer in men.
- Castration-resistant prostate cancer (CRPC) poses significant treatment challenges, especially resistance to enzalutamide (Enz).
- Histone modifications, including methylation and acetylation, are implicated in the development of Enz resistance.
Purpose of the Study:
- To review recent findings on how histone modification patterns change during PCa progression and drug resistance.
- To explore the role of the tumor microenvironment's signaling pathways in regulating histone-modifying enzymes.
- To discuss potential combination therapies for overcoming Enz resistance in PCa.
Main Methods:
- Literature review of studies investigating histone modifications in PCa and Enz resistance.
- Analysis of research on signaling pathways affecting histone-modifying enzymes.
- Synthesis of current knowledge on therapeutic strategies targeting epigenetic alterations.
Main Results:
- Altered histone methylation and acetylation patterns are linked to Enz resistance in CRPC.
- Changes in histone modifications occur in drug resistance-related genes as PCa progresses.
- Tumor microenvironment signaling pathways influence histone-modifying enzyme activity, impacting Enz efficacy.
Conclusions:
- Histone modification patterns are critical determinants of enzalutamide efficacy in prostate cancer.
- Targeting epigenetic alterations offers promising avenues for novel therapeutic strategies.
- Combination therapies hold potential for reversing drug resistance and improving clinical outcomes in CRPC.
Related Concept Videos
Histone Modification
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
Spreading of Chromatin Modifications
Writers
The writer...
Histone Variants at the Centromere
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Epigenetic Regulation
X-chromosome...
Chromatin Structure Regulates pre-mRNA Processing
The chromatin structure, especially...


